Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases

Rademikibart (CBP-201) is a next-generation human monoclonal antibody targeting IL-4Rα, undergoing evaluation in Phase 2 clinical trials for the treatment of moderate-to-severe Th2 inflammatory diseases. We report the immunological characterization of rademikibart. Rademikibart and dupilumab were as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Limin, Ding, Ying, Wang, Qingjian, Pan, Wubin, Wei, Zheng, Smith, Paul A., Yang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390583/
https://www.ncbi.nlm.nih.gov/pubmed/37524768
http://dx.doi.org/10.1038/s41598-023-39311-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390583/
https://www.ncbi.nlm.nih.gov/pubmed/37524768
http://dx.doi.org/10.1038/s41598-023-39311-2

Ejemplares similares